Document is current
Any future updates will be listed below
-
Authors
Pantel, Klaus
Alix-Panabières, Catherine
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02866149 at ClinicalTrials.govnct02866149 at ClinicalTrials.govDocuments that mention this clinical trial
Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation
https://doi.org/10.1136/jitc-2022-005615
nct02866149 at ClinicalTrials.govDocuments that mention this clinical trial
Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation
https://doi.org/10.1136/jitc-2022-005615
nct01710605 at ClinicalTrials.govDocuments that mention this clinical trial
Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation
https://doi.org/10.1136/jitc-2022-005615
Documents that mention this clinical trial
Crucial roles of circulating tumor cells in the metastatic cascade and tumor immune escape: biology and clinical translation
https://doi.org/10.1136/jitc-2022-005615
Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial
https://doi.org/10.1200/jco.23.00456
-
Funding
Funding for this research was provided by:
The National Institute of Cancer (N/A)
Deutsche Krebshilfe (70112504)
Deutsche Forschungsgemeinschaft (SPP2084)
ERA-NET EU/TRANSCAN 2 JTC 2016 PROLIPSY (N/A)
European Union Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie grant (No 765492)
SIRIC Montpellier Cancer (Grant INCa_Inserm_DGOS_12553)
ERC Advanced Investigator Grant INJURMET (834974)
CANCER-ID (115749-CANCER-ID)
- License Information
